Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STXS Stock Forecast 2025-2026
$2.20
Current Price
$189.20M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STXS Price Targets
+127.3%
To High Target of $5.00
+104.5%
To Median Target of $4.50
+81.8%
To Low Target of $4.00
STXS Price Momentum
+3.3%
1 Week Change
-2.2%
1 Month Change
+22.9%
1 Year Change
-3.5%
Year-to-Date Change
-19.1%
From 52W High of $2.72
+42.9%
From 52W Low of $1.54
📊 TOP ANALYST CALLS
Did STXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stereotaxis is one of their latest high-conviction picks.
Latest STXS Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, STXS has a bullish consensus with a median price target of $4.50 (ranging from $4.00 to $5.00). Currently trading at $2.20, the median forecast implies a 104.5% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 127.3% upside. Conversely, the most conservative target is provided by Frank Takkinen at Lake Street, suggesting a 81.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STXS Analyst Ratings
4
Buy
0
Hold
0
Sell
STXS Price Target Range
Low
$4.00
Average
$4.50
High
$5.00
Current: $2.20
Latest STXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $5.00 |
| Mar 5, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Jan 10, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $5.00 |
| Mar 6, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Mar 6, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $5.50 |
| Mar 6, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $5.00 |
| Nov 11, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $5.00 |
| Sep 2, 2022 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Jul 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $6.00 |
| Jun 23, 2022 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Jan 5, 2022 | Craig-Hallum | Buy | Initiates | $0.00 | |
| Jan 5, 2022 | Loop Capital | Buy | Initiates | $0.00 | |
| May 26, 2021 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Sep 8, 2020 | Northland Capital Markets | Outperform | Initiates | $0.00 | |
| Apr 9, 2020 | Cowen & Co. | Outperform | Initiates | $0.00 |
Stereotaxis Inc. (STXS) Competitors
The following stocks are similar to Stereotaxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Stereotaxis Inc. (STXS) Financial Data
Stereotaxis Inc. has a market capitalization of $189.20M with a P/E ratio of -7.1x. The company generates $27.51M in trailing twelve-month revenue with a -92.2% profit margin.
Revenue growth is +8.6% quarter-over-quarter, while maintaining an operating margin of -79.4% and return on equity of -179.8%.
Valuation Metrics
Market Cap
$189.20M
Enterprise Value
$182.88M
P/E Ratio
-7.1x
PEG Ratio
-12.2x
Price/Sales
6.9x
Growth & Margins
Revenue Growth (YoY)
+8.6%
Gross Margin
+54.4%
Operating Margin
-79.4%
Net Margin
-92.2%
EPS Growth
+8.6%
Financial Health
Cash/Price Ratio
+5.6%
Current Ratio
1.1x
Debt/Equity
71.8x
ROE
-179.8%
ROA
-34.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stereotaxis Inc. (STXS) Business Model
About Stereotaxis Inc.
What They Do
Develops robotic systems for minimally invasive surgery.
Business Model
The company generates revenue through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System, which enhances the precision and safety of cardiac arrhythmia treatments. By targeting hospitals and medical centers specializing in interventional cardiology, Stereotaxis aims to improve patient outcomes while optimizing operational workflows.
Additional Information
Stereotaxis is based in St. Louis, Missouri, and is actively contributing to advancements in the medical device market, focusing on innovation in robotic surgery to increase its market presence.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
139
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Country
United States
IPO Year
2004
Website
www.stereotaxis.comStereotaxis Inc. (STXS) Latest News & Analysis
Latest News
Quick Summary
Stereotaxis, Inc. (NYSE: STXS) will hold its Q1 2025 Earnings Conference Call on May 12, 2025, at 4:30 PM ET. Key executives and analysts will participate.
Why It Matters
The Q1 2025 earnings call for Stereotaxis provides insights into the company's financial performance, strategic direction, and market position, impacting investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) reported its first-quarter financial results for 2025, focusing on its leadership in surgical robotics for minimally invasive procedures.
Why It Matters
Stereotaxis' Q1 financial results can impact stock performance, reflecting company growth and market position in surgical robotics, which may influence investor sentiment and valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis Inc. (STXS) reported a quarterly loss of $0.07 per share, matching the Zacks Consensus Estimate, compared to a loss of $0.06 per share in the same quarter last year.
Why It Matters
Stereotaxis Inc.'s consistent quarterly loss signals stability in earnings expectations, but the slight increase in loss year-over-year may raise concerns about growth potential.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) will release its Q1 2025 financial results on May 12, 2025, after market close, followed by a conference call at 4:30 p.m. EST to discuss the results.
Why It Matters
Stereotaxis' upcoming financial results and conference call may influence stock performance, guiding investor sentiment and expectations regarding the company's growth and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) will demonstrate its GenesisX Robotic System live at the Heart Rhythm Symposium in San Diego from April 24-27, showcasing its capabilities and installation process.
Why It Matters
The live demonstration of the GenesisX Robotic System could enhance Stereotaxis's market visibility and attract potential buyers, impacting sales and stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Investing in surgical robotics stocks such as ISRG, ZBH, and STXS is expected to be profitable for investors in 2025.
Why It Matters
Positive projections for surgical robotics stocks signal potential growth, indicating a favorable investment opportunity in the healthcare tech sector for 2025.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About STXS Stock
What is Stereotaxis Inc.'s (STXS) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Stereotaxis Inc. (STXS) has a median price target of $4.50. The highest price target is $5.00 and the lowest is $4.00.
Is STXS stock a good investment in 2026?
According to current analyst ratings, STXS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.20. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STXS stock?
Wall Street analysts predict STXS stock could reach $4.50 in the next 12 months. This represents a 104.5% increase from the current price of $2.20. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stereotaxis Inc.'s business model?
The company generates revenue through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System, which enhances the precision and safety of cardiac arrhythmia treatments. By targeting hospitals and medical centers specializing in interventional cardiology, Stereotaxis aims to improve patient outcomes while optimizing operational workflows.
What is the highest forecasted price for STXS Stereotaxis Inc.?
The highest price target for STXS is $5.00 from Jason Wittes at Roth MKM, which represents a 127.3% increase from the current price of $2.20.
What is the lowest forecasted price for STXS Stereotaxis Inc.?
The lowest price target for STXS is $4.00 from Frank Takkinen at Lake Street, which represents a 81.8% increase from the current price of $2.20.
What is the overall STXS consensus from analysts for Stereotaxis Inc.?
The overall analyst consensus for STXS is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.50.
How accurate are STXS stock price projections?
Stock price projections, including those for Stereotaxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 11:20 PM UTC